GlassScriptPhysician profile
Susan M Utley
NPI 1366525388
$194,006.47
in general payments reported to CMS, 2019-2025
60 companies · $39K in 2025
The $39K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27K · 2022: $44K · 2023: $52K · 2024: $32K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62K · Travel and Lodging: $23K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $20K · Food and Beverage: $14K · Consulting Fee: $4,125 · Education: $756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62,210.92 |
| Travel and Lodging | $22,632.57 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $19,977.50 |
| Food and Beverage | $13,628.79 |
| Consulting Fee | $4,125.00 |
| Education | $755.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $69,393.18 | 2021-2025 | Calquence, Imfinzi, Tagrisso |
| Exelixis INC. | $46,707.99 | 2022-2025 | Cabometyx |
| Seagen INC. | $18,048.22 | 2021-2023 | Padcev, Tukysa |
| Astellas Pharma US INC | $13,743.81 | 2021-2025 | Padcev, Vyloy, Xtandi |
| Beigene USA, INC. | $10,593.58 | 2023-2025 | Brukinsa |
| Emd Serono, INC. | $7,457.67 | 2022-2025 | Bavencio |
| Epizyme, INC. | $6,411.74 | 2021-2022 | |
| Pfizer INC. | $6,097.49 | 2022-2025 | |
| Amgen INC. | $5,958.04 | 2021-2024 | Kyprolis, Imdelltra (Amg 757), Lumakras |
| Janssen Biotech, INC. | $1,128.58 | 2022-2025 | Rybrevant, Erleada, Tecvayli |
| Bayer Healthcare Pharmaceuticals INC. | $844.21 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $573.10 | 2021-2025 | Libtayo |
| Lilly USA, LLC | $469.96 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Novartis Pharmaceuticals Corporation | $469.16 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $447.06 | 2022-2025 | Opdivo, Opdualag, Krazati |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $423.19 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Daiichi Sankyo INC. | $401.18 | 2021-2025 | Enhertu |
| Genzyme Corporation | $293.41 | 2022-2025 | |
| Abbvie INC. | $290.14 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $271.49 | 2021-2025 | Fotivda |
| Glaxosmithkline, LLC. | $239.21 | 2022-2025 | Jemperli, Zejula, Ojjaara |
| Kite Pharma, INC. | $223.49 | 2023-2024 | |
| Ipsen Biopharmaceuticals, INC | $223.25 | 2023-2024 | Tazverik |
| Gilead Sciences, INC. | $176.83 | 2023-2025 | Trodelvy |
| Pharmacosmos Therapeutics INC. | $175.88 | 2024-2025 | Monoferric, Cosela |
| Servier Pharmaceuticals LLC | $172.19 | 2022-2024 | |
| Celgene Corporation | $171.87 | 2022-2025 | Reblozyl, Opdivo, Opdualag |
| Cti Biopharma Corp. | $164.30 | 2022-2023 | Vonjo |
| Incyte Corporation | $160.36 | 2022-2025 | Pemazyre, Monjuvi, Niktimvo |
| Jazz Pharmaceuticals INC. | $160.09 | 2024-2025 | |
| Eisai INC. | $158.87 | 2023-2025 | |
| Novocure INC. | $152.69 | 2024 | Optune Lua (Novottf-200t) |
| Tempus Ai, INC | $151.59 | 2025 | Xt Cdx |
| Pharmaessentia USA Corporation | $144.94 | 2023-2025 | Besremi |
| Adaptive Biotechnologies Corporation | $142.01 | 2023 | Clonoseq |
| Immunocore Limited | $127.46 | 2025 | Kimmtrak |
| Genentech USA, INC. | $106.78 | 2022-2025 | Tecentriq, Polivy, Phesgo |
| Taiho Oncology, INC. | $104.97 | 2023-2025 | |
| Tersera Therapeutics LLC | $85.98 | 2022-2024 | Zoladex, Xermelo |
| Sanofi-Aventis U.S. LLC | $79.75 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.04 | 2024-2025 | Gilotrif |
| Deciphera Pharmaceuticals INC. | $69.62 | 2024-2025 | Qinlock, Romvimza |
| Pharmacyclics LLC, An Abbvie Company | $69.38 | 2022-2023 | Imbruvica |
| Stemline Therapeutics INC. | $65.16 | 2024-2025 | Orserdu |
| Puma Biotechnology, INC. | $59.93 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $55.82 | 2024 | Ultomiris |
| Sobi, INC | $53.34 | 2024-2025 | |
| Array Biopharma INC | $45.74 | 2023-2025 | Mektovi, Lorbrena, Braftovi |
| Mirati Therapeutics, INC. | $41.78 | 2023-2024 | Krazati |
| Beone Medicines USA, INC. | $39.90 | 2025 | Tevimbra, Brukinsa |
| Foundation Medicine, INC. | $37.87 | 2023 | |
| Sumitomo Pharma America, INC. | $33.46 | 2024-2025 | Orgovyx |
| Fennec Pharmaceuticals, INC. | $31.58 | 2025 | Fyarro |
| Rigel Pharmaceuticals, INC. | $29.79 | 2024 | Tavalisse, Rezlidhia |
| Takeda Pharmaceuticals U.S.A., INC. | $27.54 | 2025 | Ninlaro |
| Organon LLC | $27.43 | 2023 | Ontruzant |
| Secura Bio, INC. | $26.61 | 2024 | Copiktra |
| Sun Pharmaceutical Industries INC. | $25.80 | 2024 | |
| Janssen Pharmaceuticals, INC | $21.73 | 2023 | Xarelto |
| Geron Corporation | $21.24 | 2025 | Rytelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Utley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.